Introduction Despite the availability of diagnostic tests and effective treatment, there has been a problem with vigilance and reporting of that infectious disease in many countries including Poland. Aim To compare the incidence of syphilis in Poland in years 2010–2016 according to the mandatory epidemiological surveillance system with the data of the National Health Fund (NHF). Material and methods Data of the NHF in Poland were collected. The total number of patients with syphilis (all forms) was estimated on the basis of their unique identifying numbers (PESEL). Results The steady increase in the incidence of syphilis in Poland throughout 2010–2016 was found, apart from the congenital form of the disease, which decreased since 2010. The higher prevalence of syphilis was noted in men. The number of hospitalized patients remained constant. According to the data of the NHF, the number of cases of syphilis in Poland was twofold higher as compared to the statistics of the mandatory epidemiological surveillance system (National Institute of Public Health – National Institute of Hygiene, NIPH-NIH), which was the basis of reports published up to date. Conclusions Our work shows that there is a remarkable underreporting of syphilis in the mandatory epidemiological surveillance system in Poland, involving also hospitalized patients. The use of the data of NHF in the surveillance of syphilis in Poland is proposed.
The aim of the study was to estimate the overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib. Material and methods: Real-world patients who received afatinib, erlotinib or gefitinib between 1 July 2012 and 30 October 2017 were analysed in five subgroups. Results: Among 267 patients treated with afatinib financed as the first line of treatment, 76 (28.46%) deaths occurred. Median observation time was 12.8 months (95% CI: 11.2-13.9). Median OS was 22.8 months (95% CI: 19.2-27.1). Among 83 patients who received erlotinib financed exclusively as the second line of treatment the number of deaths was 74 (89.16%). Median observation time was 64.3 months (95% CI: 60.4-64.6). Median OS was 16 months (95% CI: 13.2-22.9). Among 622 patients who received erlotinib financed both as first and second line treatment, there were 400 (64.3%) deaths. Median observation time was 33.3 months (95% CI: 31.2-37.6). Median OS was 17.8 months (95% CI: 16.4-19.7). Among 137 patients who received gefitinib financed only as the first line of treatment, there were 128 (93.4%) deaths. Median observation time was 58.3 months (95% CI: 49.4-62.5). Median OS was 16 months (95% CI: 13.8-19.7). Among 348 patients who received gefitinib financed both as the first and second line of treatment the number of deaths was 208 (59.8%). Median observation time was 23.7 months (95% CI: 20.7-28.7). Median OS was 15.5 months (95% CI: 12.9-17.5). Conclusions: Our real-world data regarding OS confirm the benefits found in clinical trials from the use of afatinib, erlotinib or gefitinib. However, the lower overall survival rate of Polish patients compared to similar studies from other research centres suggests the need for deeper investigation of this issue.
IntroductionIn Poland, it is uniquely possible to assess real effects of the introduction of new oncological therapies on the overall survival in patients as such therapies are funded by one payer only – the National Health Fund (NHF). Data collected by the NHF make it possible to analyse the survival of all patients who were diagnosed with melanoma.AimThe paper presents findings of a retrospective analysis of the efficacy of systemic treatment in patients with malignant melanoma of the skin in Poland with regard to the overall survival.Material and methodsThe analysis of the overall survival was performed with the Kaplan-Meier method in the population receiving systemic treatment. Three groups of patients were analysed. Group 1 included all patients who had started systemic treatment between 1 March 2011 and 1 March 2015: 1,258 patients. The median overall survival was 8.4 months. Group 2 included 444 patients who had started systemic treatment between 1 March 2011 and 28 February 2013. The median overall survival was 6.6 months in this group. Group 3 included 814 patients who had started systemic treatment between 1 March 2013 and 1 March 2015 and included 546 patients who were also treated in drug programmes with ipilimumab and vemurafenib (approx. 67%). The median overall survival was 9.4 months.ResultsA difference in the overall survival between group 3 and 2 was statistically significant (p < 0.05).ConclusionsThe introduction of vemurafenib and ipilimumab into systemic treatment in Poland using public funds had a significant effect on the prolongation of the overall survival in patients with malignant melanoma of the skin.
a b s t r a c tAim: Assessment of long-term safety and effectiveness of atazanavir in the first cART regimen. Background: Achievement of longer life span in recent years increased HIV-positive patients' risk of experiencing conditions resulting from long term cART therapy including drug-induced toxicities like metabolic, hepatic or renal disorders. Materials and methods: The study is a retrospective analysis of data collected in POLCA cohort. Safety analyses included changes in selected parameters: hepatic (ALT, AST, GGT, bilirubin, INR), metabolic (glucose, cholesterol, triglycerides) and renal (creatinine, urea). Effectiveness analyses included CD4 count on treatment vs. baseline and proportion of patients with durable VL suppression. Results: After 12 and 24 months from starting treatment VL below 40 copies/mL had 60% and 56% of patients, respectively. VL below 200 copies/mL after 12 and 24 months had 80% and 76% of patients, respectively. The median CD4 count increased from baseline at all time points, and at 24 months was equal in late presents (baseline CD4 <350) and the whole group. Proportion of patients with normal levels of liver function parameters did not change significantly between baseline and treatment with exception of significant decrease for bilirubin. Differences in lipids and glucose levels did not change significantly between baseline and treatment with exception of significant increase for HDL at 24 months. Renal function parameters remained unchanged between baseline and treatment. Conclusion: In POLCA cohort long term treatment with ATV was safe and effective, and observed druginduced toxicities were similar or smaller than reported in literature.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.